NASDAQ:IMV IMV (IMV) Stock Price, News & Analysis → Fidelity, Bezos, Goldman Bet Big on Tiny Biotech (From Behind the Markets) (Ad) Free IMV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.49▼$0.9152-Week Range N/AVolume44,800 shsAverage Volume233,607 shsMarket Capitalization$9.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get IMV alerts: Email Address Ad Behind the MarketsFidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.Don't miss out on the "next Ozempic" >>> About IMV Stock (NASDAQ:IMV)IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.Read More Ad Behind the MarketsFidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.Don't miss out on the "next Ozempic" >>> IMV Stock News HeadlinesMay 8, 2024 | finanznachrichten.deInflaRx N.V.: InflaRx Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | msn.comThe Kremlin scores propaganda points with a display of captured tanks and armour ahead of the Victory Day paradeMay 8, 2024 | Behind the Markets (Ad)Fidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.May 3, 2024 | finance.yahoo.comBioVaxys Technology Corp. Closes First Tranche of Private PlacementMay 2, 2024 | msn.comO.J. Simpson's lawyer ready to meet with Goldman, Brown familiesMay 2, 2024 | msn.comCancer: Monthly horoscope MayApril 30, 2024 | finanznachrichten.deBioVaxys Technology Corp.: Biovaxys Appoints Christopher Cherry As Chief Financial OfficerApril 13, 2024 | msn.comGolden Bachelor news: Gerry and Theresa break up, but still love each otherMay 8, 2024 | Behind the Markets (Ad)Fidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.April 7, 2024 | msn.comThe Pros And Cons Of Owning Toyota's $13,000 Pickup TruckApril 3, 2024 | msn.comWhy are there so many cars in Omaha without license plates?April 3, 2024 | msn.comVirginia Tech hires Marquette's Megan Duffy as new coachMarch 28, 2024 | finanznachrichten.deCalciMedica, Inc.: CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate UpdatesMarch 27, 2024 | msn.comPhilippines sales up in February 2024March 26, 2024 | msn.comAn Electric Toyota Hilux Is Reportedly Coming by 2025March 26, 2024 | msn.comThe New FJ Cruiser Could Use Toyota's $13,000 Truck PlatformMarch 25, 2024 | theguardian.comAsian hornet may have become established in UK, sighting suggestsMarch 22, 2024 | finanznachrichten.deBioVaxys Technology Corp.: BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENTMarch 21, 2024 | finance.yahoo.comBioVaxys Technology Corp. Provides Bi-Weekly MCTO Status UpdateMarch 13, 2024 | msn.com16 Things We Know About the All-New 2024 Chevelle 70/SSMarch 11, 2024 | msn.comPotential Return of Toyota FJ Cruiser with Utilization of Hilux Champ’s PlatformMarch 8, 2024 | msn.comToyota Mini Fortuner launch compact Fortuner price Scorpio N line mini fortuner featuresMarch 8, 2024 | msn.comVersatile, Vigorous, and Victorious: The Toyota Hilux Champ Dominates the StageMarch 7, 2024 | msn.comToyota FJ to return as a sub-LandCruiser sized SUV – reportMarch 7, 2024 | msn.comRugged New Fortuner-Based Smaller SUV Could Cost Rs 25 lakh?March 5, 2024 | finanznachrichten.deBioVaxys Technology Corp.: BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent ApplicationsMarch 5, 2024 | finance.yahoo.comBioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent ApplicationsSee More Headlines Receive IMV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMV CUSIPN/A CIK1734768 Webimv-inc.com Phone(902) 492-1819FaxN/AEmployees97Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,990,000.00 Net Margins-11,547.42% Pretax Margin-11,547.42% Return on Equity-12,695.41% Return on Assets-104.84% Debt Debt-to-Equity RatioN/A Current Ratio2.93 Quick Ratio2.93 Sales & Book Value Annual Sales$330,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.69) per share Price / BookN/AMiscellaneous Outstanding Shares11,712,000Free Float11,673,000Market Cap$9.63 million OptionableOptionable Beta0.95 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesAndrew HallChief Executive Office & DirectorJennifer SchmitkeChief Operating OfficerBrittany DavisonChief Accounting Officer, Director & SVP-financeJeremy R. GraffChief Scientific OfficerStéphane FisetVice President-Clinical ResearchKey CompetitorsGalera TherapeuticsNASDAQ:GRTXAddex TherapeuticsNASDAQ:ADXNAeterna ZentarisNASDAQ:AEZSAlterity TherapeuticsNASDAQ:ATHEChemomab TherapeuticsNASDAQ:CMMBView All Competitors IMV Stock Analysis - Frequently Asked Questions How were IMV's earnings last quarter? IMV Inc. (NASDAQ:IMV) issued its earnings results on Thursday, November, 11th. The company reported ($1.30) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.30). The company earned $0.04 million during the quarter. IMV had a negative trailing twelve-month return on equity of 12,695.41% and a negative net margin of 11,547.42%. During the same quarter in the previous year, the company earned ($1.00) earnings per share. When did IMV's stock split? Shares of IMV reverse split before market open on Tuesday, December 13th 2022. The 1-10 reverse split was announced on Tuesday, December 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. This page (NASDAQ:IMV) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorFidelity, Bezos, Goldman Bet Big on Tiny BiotechBehind the MarketsAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMV Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.